Back to Search
MARK MESSING, MD
MD
Gynecologic Oncology Physician
NPI: 1932141033IndividualAccepts Medicare
Specialties, Licenses & Credentials
Gynecologic Oncology PhysicianPrimary
Obstetrics & Gynecology — Gynecologic Oncology
Code: 207VX0201X
H7467(TX)
CMS Specialties
PrimaryGYNECOLOGICAL ONCOLOGY
Education
EMORY UNIVERSITY SCHOOL OF MEDICINE
Class of 1984
Research & Publications (6)
Vascular endothelial growth factor-stimulated cerebral microvascular endothelial cells mediate the recruitment of neural stem cells to the neurovascular niche.
PMID 19285048·Brain Res·2009
7-preclinical
Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer.
PMID 19224848·J Clin Oncol·2009
3-trial
Controlled polytypic and twin-plane superlattices in iii-v nanowires.
PMID 19119283·Nat Nanotechnol·2009
8-other
Recombinant activated factor VII in the treatment of near-fatal bleeding during pediatric brain tumor surgery. Report of two cases and review of the literature.
PMID 16509483·J Neurosurg·2006
5-case
Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.
PMID 15297200·Gynecol Oncol·2004
3-trial
Phase I study of alternating doublets of topotecan/carboplatin and paclitaxel/carboplatin in patients with newly diagnosed, advanced ovarian cancer.
PMID 11925132·Gynecol Oncol·2002
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1615 HOSPITAL PKWY, SUITE 300
BEDFORD, TX 76022 - Phone
- (817) 354-5581
Quick Facts
- NPI
- 1932141033
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 42
- Publications
- 6
Are you this provider?
Claim Your Profile